See more : Great Eastern Holdings Limited (G07.SI) Income Statement Analysis – Financial Results
Complete financial analysis of Vera Therapeutics, Inc. (VERA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vera Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Azbil Corporation (6845.T) Income Statement Analysis – Financial Results
- Liquidity Services, Inc. (LQDT) Income Statement Analysis – Financial Results
- Driver Group plc (DRV.L) Income Statement Analysis – Financial Results
- The Hongkong and Shanghai Hotels, Limited (HKSHY) Income Statement Analysis – Financial Results
- HANDOK Inc. (002390.KS) Income Statement Analysis – Financial Results
Vera Therapeutics, Inc. (VERA)
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 1.86M | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 0.00 | -846.00K | 176.00K | 251.00K | 509.00K |
Gross Profit | 1.86M | 846.00K | -176.00K | -251.00K | -509.00K |
Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 78.23M | 68.99M | 22.48M | 45.21M | 7.29M |
General & Administrative | 23.79M | 21.91M | 11.92M | 4.04M | 4.41M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 23.79M | 21.91M | 11.92M | 4.04M | 4.41M |
Other Expenses | 0.00 | 1.85M | 1.79M | -1.08M | 0.00 |
Operating Expenses | 102.01M | 90.90M | 34.40M | 49.25M | 11.70M |
Cost & Expenses | 102.01M | 90.90M | 34.40M | 49.25M | 11.70M |
Interest Income | 4.19M | 1.75M | 15.00K | 8.00K | 159.00K |
Interest Expense | 0.00 | 992.00K | 20.00K | 166.00K | 51.00K |
Depreciation & Amortization | 0.00 | -846.00K | 176.00K | 251.00K | 509.00K |
EBITDA | -102.01M | -90.90M | -34.23M | -53.00M | -11.19M |
EBITDA Ratio | -5,478.63% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -102.01M | -90.90M | -34.40M | -52.24M | -11.96M |
Operating Income Ratio | -5,478.63% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 6.02M | 1.85M | 1.79M | -1.17M | 108.00K |
Income Before Tax | -95.99M | -89.06M | -32.61M | -53.41M | -11.85M |
Income Before Tax Ratio | -5,155.16% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
Net Income | -95.99M | -89.06M | -32.61M | -53.41M | -11.85M |
Net Income Ratio | -5,155.21% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -2.25 | -3.35 | -1.53 | -14.40 | -3.46 |
EPS Diluted | -2.25 | -3.35 | -1.53 | -14.40 | -3.46 |
Weighted Avg Shares Out | 42.71M | 26.57M | 21.28M | 3.71M | 3.42M |
Weighted Avg Shares Out (Dil) | 42.71M | 26.57M | 21.28M | 3.71M | 3.42M |
Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results
Vera: New Kidney Data, May Be A Potential Next Big Pharma M&A Target
Vera: Repurposed Molecule Program Does Not Impress
Why Shares of Vera Therapeutics Jumped Tuesday
Vera Therapeutics shares surge on positive IgAN trial results
2 Surging Healthcare Stocks With More Fuel in the Tank
Novartis deal for Chinook makes kidney-treatment competitors more attractive, analysts say
Why Shares of Vera Therapeutics Are Soaring Monday
7 Stocks That Wall Street Analysts Are Loving in June
Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports